GW Pharmaceuticals (GWPH)

Contact Information

About this Organization

GW Pharmaceuticals was founded in 1998 and is listed on both the NASDAQ Global Market (GWPH) and AIM, a market of the London Stock Exchange. GW is licensed by the UK Home Office to work with a range of controlled drugs for medical research purposes.

The Group’s lead programme is the development of a product portfolio of cannabinoid prescription medicines to meet patient needs in a wide range of therapeutic indications, including Sativex® Oromucosal Spray and Epidiolex® for childhood epilepsy.

Associates

Ethan Russo, MD, is a board-certified neurologist, psychopharmacology researcher, and former Senior Medical Advisor to GW Pharmaceuticals. He served as study physician to GW Pharmaceuticals for three Phase III clinical trials of Sativex. Ethan Russo graduated from the University of Pennsylvania (Psychology) and the University of Massachusetts Medical School, before residencies in Pediatrics in Phoenix, Arizona and in Child and Adult Neurology at the University of Washington in Seattle. He was a clinical neurologist in Missoula, Montana for 20 years in a practice with a strong chronic pain component. In 1995, he pursued a 3-month sabbatical doing ethnobotanical research with …

In The News

The FDA announced in a press release on Monday that it had approved the “first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy.” Prior to this week, the U.S. Food and Drug Administration (FDA) had approved only three cannabinoid-based medicines. None of the approved drugs contain, or are derived from, the whole cannabis plant. Instead, they are all created from isolated synthetics that do not offer the benefits of the entourage effect. FDA Grants Approval of Epidiolex On June 26, 2018, the FDA granted approval of Epidiolex, …

Epilepsy is a common neurological disorder experienced by children, and approximately 20% of patients (around 93,200 children in the US, and around 153,000 children in Europe) are unable to control their seizures with commonly used medications. Due to the growing evidence that some cannabinoids found in cannabis may help to reduce neuron hyperexcitability, certain strains are being used to help treat epilepsy. This is particularly true of cannabis strains with a high concentration of cannabidiol (CBD). In turn, pharmaceutical companies have been working on ways repeat …

Similar Companies

Based in Fort Lauderdale, Florida, Cannabis Biotech is a subsidiary of Puget Technologies (OTC: PUGE). The publicly held company is led by President and CEO Ron Leyland. Cannabis Biotech conducts research to develop innovative cannabinoid products and therapies for the treatment of diseases and their symptoms. Ailments that the company has studied include HIV, cancer, glaucoma and neurological disorders. Thus far, Cannabis Biotech has developed a number of products that utilize alternative delivery methods. For instance, they have developed nasal spray and trans-dermal skin patches geared towards treatment via cannabinoids. Further, they are developing cannabis infused beverages that utilize natural …

WEED, Inc., (OTC Pink: BUDZ), is a public company focused on purchasing land and building Commercial Grade “Cultivation Centers” to consult, assist, manage & lease to Licensed Dispensary owners and organic grow operators on a contract basis, with a concentration on the legal and medical marijuana sector. The Company’s plan is to become a True “Seed-to-Sale” company providing infrastructure, financial solutions and real estate options in this new emerging market.

Puget Technologies (OTCQB: PUGE) is a publicly traded company focused on investing in companies that stay ahead of the curve and offer innovative products. Cannabis Biotech, a wholly owned subsidiary of Puget Technologies, is forging new frontiers in cannabinoid research and distribution. As the world grows to accept cannabis-based medicines, we are poised to meet the demand. Its other subsidiary, B-29, is responsible for manufacturing naturally-infused energy drinks.

DISCLAIMER: The professionals and companies described are not associated or affiliated with Medical Jane, and they
may not endorse Medical Jane or the information provided. The names of other companies, products and services are
the property of their respective owners.

Whether you are a new or experienced cannabis consumer, Medical Jane’s step-by-step patient guides will help you find your optimal dosage and delivery method to achieve optimal results using medical cannabis.